Medpace Holdings, Inc. $MEDP Shares Sold by Ranger Investment Management L.P.

Ranger Investment Management L.P. decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 27.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,875 shares of the company’s stock after selling 18,872 shares during the quarter. Medpace accounts for about 1.8% of Ranger Investment Management L.P.’s holdings, making the stock its 24th largest holding. Ranger Investment Management L.P. owned 0.17% of Medpace worth $25,130,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quent Capital LLC acquired a new stake in Medpace in the 3rd quarter valued at $25,000. Root Financial Partners LLC acquired a new stake in shares of Medpace in the third quarter valued at about $38,000. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of Medpace by 35.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new position in Medpace in the 2nd quarter valued at about $36,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

Medpace stock opened at $548.05 on Friday. The firm has a 50 day simple moving average of $580.60 and a 200-day simple moving average of $536.29. The stock has a market cap of $15.44 billion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.89 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. TD Cowen reaffirmed a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Barclays increased their target price on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Finally, Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $491.27.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. The trade was a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 320,192 shares of company stock valued at $192,909,762. Company insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.